Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition

• Published in: Blood advances Vol. 6; no. 2; pp. 611 - 623
• Main Authors: Kong, Tim, Laranjeira, Angelo B.A., Collins, Taylor B., De Togni, Elisa S., Wong, Abigail J., Fulbright, Mary C., Ruzinova, Marianna, Celik, Hamza, Challen, Grant A., Fisher, Daniel A.C., Oh, Stephen T.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 25.01.2022; American Society of Hematology
• Subjects: Animals; Cyclopentanes - therapeutic use; Humans; Leukemia, Myeloid, Acute - pathology; Mice; Myeloid Neoplasia; Myeloproliferative Disorders - drug therapy; Myeloproliferative Disorders - pathology; Primary Myelofibrosis - pathology; Pyrimidines
• DOI: 10.1182/bloodadvances.2020002804
• ISSN: 2473-9529; 2473-9537

Targeted inhibitors of JAK2 (eg ruxolitinib) often provide symptomatic relief for myeloproliferative neoplasm (MPN) patients, but the malignant clone persists and remains susceptible to disease transformation. These observations suggest that targeting alternative dysregulated signaling pathways may provide therapeutic benefit. Previous studies identified NFκB pathway hyperactivation in myelofibrosis (MF) and secondary acute myeloid leukemia (sAML) that was insensitive to JAK2 inhibition. Here, we provide evidence that NFκB pathway inhibition via pevonedistat targets malignant cells in MPN patient samples as well as in MPN and patient-derived xenograft mouse models that are nonredundant with ruxolitinib. Colony forming assays revealed preferential inhibition of MF colony growth compared with normal colony formation. In mass cytometry studies, pevonedistat blunted canonical TNFα responses in MF and sAML patient CD34+ cells. Pevonedistat also inhibited hyperproduction of inflammatory cytokines more effectively than ruxolitinib. Upon pevonedistat treatment alone or in combination with ruxolitinib, MPN mouse models exhibited reduced disease burden and improved survival. These studies demonstrating efficacy of pevonedistat in MPN cells in vitro as well as in vivo provide a rationale for therapeutic inhibition of NFκB signaling for MF treatment. Based on these findings, a Phase 1 clinical trial combining pevonedistat with ruxolitinib has been initiated. •Pevonedistat targets the NFκB pathway to inhibit growth of MPN and sAML cells.•Pevonedistat reduces disease burden in MPN mouse models. [Display omitted]